| From: chowder | 5/3/2021 1:50:59 PM | | | | | | Speaking of CHPT ....
ChargePoint Stock Is Still the Perfect Way to Plug Into the EV Revolution
The most obvious reason to have a position in ChargePoint (NYSE: CHPT) is because you’re bullish on the build-out of electric vehicle infrastructure. For that reason alone, you could build an argument in favor of owning CHPT stock.
Source: YuniqueB / Shutterstock.com
Another reason to own the stock is because you view ChargePoint as a “picks and shovels” type of investment.
investorplace.com |
| | Disruption Innovation | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: chowder who wrote (278) | 5/3/2021 2:44:50 PM | | From: floyddd | | | | just a little, is all i thought. i mean, you've been more silent than usual, from what i know, ever since around the time the growth correction started. and if you've been building your ARK positions during the downdraft, i don't believe you've posted about it. in fact, for a bit now, there's a giant vacancy in chowderpostville, whereas in previous days, them words were being churned out doubletime.
perhaps it's due to the difference b/ SI and SA, i dunno. or else your time has mostly been spent engaging with the cryptos. but i miss your precense. i've always found it calming. and illuminating. |
| | Disruption Innovation | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: floyddd who wrote (281) | 5/3/2021 4:02:01 PM | | From: chowder | | | | I'm still very much active in adding to the disruptive companies and especially crypto. I have been adding in other portfolios that I do not track publicly so I keep those moves to myself.
I'm not spending as much time on the message boards either since it is gardening season. |
| | Disruption Innovation | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: chowder who wrote (279) | 5/3/2021 8:44:47 PM | | From: Harper | | | | No one has ever suggested using lidar alone.
Tesla uses front-facing radar and 12-16 ultrasonic sensors, because cameras were not enough.
Lidar is probably indispensable for autonomous vehicles.
All companies talking about lidar use them in conjunction with cameras and radar.
Cameras require more complex algorithms for computers to identify the colors they see, whereas lidar is fairly straightforward in identifying objects and can measure exact distances. A computer doesn't "see" anything on a camera unless it's programmed to identify something.
Lidar can see things better than eyes, especially when there is glare that can block the human eye and camera vision.
When Musk first said he didn't want lidar it was prohibitively expensive. Now, costs have dropped and the tech is better, too.
Xpeng's newest vehicle, designed for eventual autonomous driving, uses cameras, radar, and lidar.
Teslas use cameras, radar, and ultrasonic sensors.
Tesla is working on more advanced radars as well that will simulate some of what lidar does.
Musk knows cameras alone are insufficient. |
| | Disruption Innovation | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Frank Sully | 5/6/2021 1:13:36 PM | | | | | | Global Ai In Pharma Market Report 2021: Long-term Forecast to 2025 & 2030 Featuring Novartis, IBM Watson, Microsoft, Merck, GNS Healthcare., Google, AstraZeneca, Atomwise, Exscientia, and Cyclica
Thu, May 6, 2021, 7:30 AM·5 min read
This report focuses on Ai in pharma market which is experiencing strong growth. The report gives a guide to the ai in pharma market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.
Major players in the artificial intelligence (AI) in pharma market are Novartis, IBM Watson, Microsoft Corporation, Merck, GNS Healthcare., Google, AstraZeneca, Atomwise, Inc., Exscientia, and Cyclica.
The global AI in pharma market is expected to grow from $0.91 billion in 2020 to $1.27 billion in 2021 at a compound annual growth rate (CAGR) of 39%.
The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $5.94 billion in 2025 at a CAGR of 47%.
The artificial intelligence (AI) in pharma market covered in the report is segmented by technology into context-aware processing, natural language processing, querying method, deep learning; by drug type into small molecule, large molecules; by application into diagnosis, clinical trial research, drug discovery, research and development, epidemic prediction.
North America was the largest region in the AI in pharma market in 2020. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Lack of skilled professionals may hamper the growth of artificial intelligence in the pharma market. In 2019, Indeed.com revealed that AI job postings increased 29.1% over the last year and yet, with no uncertainty due to the AI skills gap, searches for AI-related roles decreased by 14.5% over the same period.
The shortage of AI skills is seen as a major barrier to the pace of technology's adoption. In fact, 56% of senior AI professionals thought that a lack of additional, qualified AI workers was the single most important hurdle to be overcome in terms of obtaining the necessary level of AI implementation beyond business operations. Therefore, the lack of skilled professionals may hamper the growth of AI in the pharma market.
In November 2018, Cyclica, a Canadian biotechnology company that leverages AI and computational biophysics to decentralize drug discovery collaborated with Bayer on drug discovery programs. These companies will increase drug discovery applications by increasing intelligence into the polypharmacological outlines of small molecules while further developing Cyclica's integrated system of licensing technologies. Bayer, a German multinational pharmaceutical company, includes human and veterinary pharmaceuticals, agricultural chemicals, seeds, and biotechnology products.
The growing adoption of artificial intelligence (AI) for clinical trials research is driving its demand for AI in the pharmaceutical market. To bring a new drug to the market takes on an average 10-15 years approximately and half of this time is consumed during the clinical trial phases of the drug development cycle. Hence, using AI models and analytics tools can accelerate the clinical trial phases, perception of diseases, identify suitable cases and key investigators to inform site selection, and support novel clinical study designs.
For instance, in January 2020, Pfizer, an American pharmaceutical company, tied up with a biotech startup Insilico Medicine to identify drug targets. With AI tools Pfizer can speed up drug discovery and reduce drug development costs in the drug development processes. Thus, increasing the adoption of AI for clinical trials research is driving AI in the pharma market.
Companies operating in the AI for the pharma market are introducing new AI tools that will be beneficial for the pharma companies and this is a key trend in AI in the pharma market. AI helps in quality control, predictive maintenance, waste reduction, design optimization and process automation.
The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Companies Mentioned
Novartis
IBM Watson
Microsoft Corporation
Merck
GNS Healthcare
Google
AstraZeneca
Atomwise Inc.
Exscientia
Cyclica
NVIDIA Corporation
XtalPi Inc.
BenevolentAI
Cloud Pharmaceuticals Inc
BERG LLC
Bayer
Pfizer
Recursion Pharmaceuticals Inc.
Bristol-Myers Squibb |
| | Disruption Innovation | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: chowder | 5/6/2021 1:29:14 PM | | | | | | If anyone has an interest in SQ, they announce earnings after the market close today. If their report is anything like PYPL's was, it's possible SQ will show a nice pop in price. This is one example of where I will sometimes front run an earnings report as opposed to waiting post announcement.
SQ is down 3.57% as I type. I could be wrong but I'm thinking it will take a terrible report to cause price to dip much further. An earnings surprise to the upside though might cause price to have a nice pop tomorrow.
Again, this just an opinion but it is an example of how I play earnings announcements. |
| | Disruption Innovation | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| |
